Results of Haploidentical Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia
Study Overview
A multicenter, randomized, phase 3 trial assessed the efficacy and safety of haplo-cord HCT in AML patients. A total of 268 eligible patients aged 18-60 years were randomly allocated to receive haplo-cord HCT or haplo-HCT.
Main Findings
The 3-year overall survival (OS) of the haplo-cord HCT group was better than the haplo-HCT group. Favorable progression-free survival and reduced relapse rates were observed in the haplo-cord HCT group. Grade 3-4 adverse events within two years posttransplantation were similar in both groups. Haplo-cord HCT patients also showed faster neutrophil recovery and increased T-cell reconstitution posttransplantation.
Clinical Implications
Haplo-cord HCT can improve OS in AML patients without excessive AEs, which may provide additional benefits for recipients of haplo-HCT.
Clinical Trials and Healthcare Solutions
Empowering Clinicians
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates standards, protocols, and research, providing a single, easily accessible knowledge base for clinicians.
Streamlining Healthcare Operations
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, treatment monitoring, and telemedicine, making it easier to manage patient care and expand services digitally. By utilizing AI, clinics can improve workflows and patient outcomes while reducing paper-based routines.
Learn more about how we can help at aidevmd.com.
